These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1957 related articles for article (PubMed ID: 7747814)

  • 1. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.
    Gruis NA; Weaver-Feldhaus J; Liu Q; Frye C; Eeles R; Orlow I; Lacombe L; Ponce-Castaneda V; Lianes P; Latres E
    Am J Pathol; 1995 May; 146(5):1199-206. PubMed ID: 7747814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth arrest and suppression of tumorigenicity of bladder-carcinoma cell lines induced by the P16/CDKN2 (p16INK4A, MTS1) gene and other loci on human chromosome 9.
    Wu Q; Possati L; Montesi M; Gualandi F; Rimessi P; Morelli C; Trabanelli C; Barbanti-Brodano G
    Int J Cancer; 1996 Mar; 65(6):840-6. PubMed ID: 8631601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
    Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
    Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.
    Liu Q; Neuhausen S; McClure M; Frye C; Weaver-Feldhaus J; Gruis NA; Eddington K; Allalunis-Turner MJ; Skolnick MH; Fujimura FK
    Oncogene; 1995 Mar; 10(6):1061-7. PubMed ID: 7700630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infrequent somatic alteration of p16/MTS1 in human primary superficial bladder cancers.
    Okajima E; Fukuda T; Okita S; Tsutsumi M; Hirao Y; Okajima E; Konishi Y
    Cancer Lett; 1996 Jun; 103(2):227-31. PubMed ID: 8635161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
    Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
    Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines.
    Southgate J; Proffitt J; Roberts P; Smith B; Selby P
    Br J Cancer; 1995 Nov; 72(5):1214-8. PubMed ID: 7577470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased p16 levels correlate with pRb alterations in human urothelial cells.
    Yeager T; Stadler W; Belair C; Puthenveettil J; Olopade O; Reznikoff C
    Cancer Res; 1995 Feb; 55(3):493-7. PubMed ID: 7834615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
    Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
    J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
    Pollock PM; Pearson JV; Hayward NK
    Genes Chromosomes Cancer; 1996 Feb; 15(2):77-88. PubMed ID: 8834170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.
    Kamb A; Shattuck-Eidens D; Eeles R; Liu Q; Gruis NA; Ding W; Hussey C; Tran T; Miki Y; Weaver-Feldhaus J
    Nat Genet; 1994 Sep; 8(1):23-6. PubMed ID: 7987388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers.
    Yoshida S; Todoroki T; Ichikawa Y; Hanai S; Suzuki H; Hori M; Fukao K; Miwa M; Uchida K
    Cancer Res; 1995 Jul; 55(13):2756-60. PubMed ID: 7796400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
    Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
    Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
    Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
    Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers.
    Miyamoto H; Kubota Y; Fujinami K; Dobashi Y; Kondo K; Yao M; Shuin T; Hosaka M
    Oncol Res; 1995; 7(7-8):327-30. PubMed ID: 8747595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.
    Sarkar S; Jülicher KP; Burger MS; Della Valle V; Larsen CJ; Yeager TR; Grossman TB; Nickells RW; Protzel C; Jarrard DF; Reznikoff CA
    Cancer Res; 2000 Jul; 60(14):3862-71. PubMed ID: 10919661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage.
    Talve L; Sauroja I; Collan Y; Punnonen K; Ekfors T
    Int J Cancer; 1997 Jun; 74(3):255-9. PubMed ID: 9221801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma.
    Ohta M; Berd D; Shimizu M; Nagai H; Cotticelli M-G ; Mastrangelo M; Shields JA; Shields CL; Croce CM; Huebner K
    Int J Cancer; 1996 Mar; 65(6):762-7. PubMed ID: 8631588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Status and expression of the p16INK4 gene in human thyroid tumors and thyroid-tumor cell lines.
    Calabrò V; Strazzullo M; La Mantia G; Fedele M; Paulin C; Fusco A; Lania L
    Int J Cancer; 1996 Jul; 67(1):29-34. PubMed ID: 8690521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.
    Williamson MP; Elder PA; Shaw ME; Devlin J; Knowles MA
    Hum Mol Genet; 1995 Sep; 4(9):1569-77. PubMed ID: 8541841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 98.